Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Dyadic International Inc. DYAI

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$3.1M
▼ 11.6% YoY
$-7.4M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

The Company develops, manufactures, and commercializes precision-engineered, animal-free recombinant proteins and enzymes for applications in life sciences, food and nutrition, and bio-industrial markets. These products are produced using Dyadic’s proprietary microbial expression platforms, including the C1 and Dapibus™ systems, which enable scalable and cost-effective production of recombinant proteins used in research, diagnostics, cell culture, nutrition, and industrial biotechnology. The Company utilizes third-party consultants, contract research organizations, and manufacturing partners to support certain research, development, and commercial activities. For more than two decades, the Company developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins.

Written from the business description in Dyadic International, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 25 March 2026. Every sentence was checked against that document before publication.

Growth

USD 3.1M
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 3.1 · Net income -7.4
2M3M-5M-10M
2017202020232025
Compound annual growth
+1.8%
+14.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +14.0% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−238 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -232.8% · Net -238.3%
-500%
201720212025
ROE
FY2025 · ROE -397.8%
-100%-200%-300%
201720212025
Three returns, three denominators.

Each USD of equity lost 398 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Net buybacks $M Dividends $M
FY2019 · Dividends · · Net buybacks -0.6
2.5M5.0M
201720182019

Total assetsUSD 9.9M
EquityUSD 1.2M
CashUSD 4.6M
Current ratio2.68×

Equity funds 12% of total assets.

The 9-year record

9 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
DYAI, 9-year financial record
Metric 202520242023202220212020201920182017
Revenue $B0.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B◌◌◌◌◌◌◌◌◌
Income tax $B◌◌◌◌0.00.00.0−0.0−0.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.23−0.20◌◌−0.47−0.34−0.31−0.21−0.07
Dividend / sh $◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————
ROE %−397.8−139.2−80.1−66.1−55.8−29.0−21.2−12.3−4.0
Shares out B0.040.030.030.030.030.030.030.030.03

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 35 reconciliationsAUDITED

Reconciled in 9 of the 9 fiscal years we could check. 20 checks were skipped: the balance sheet is not tagged before 2017. 10 checks were skipped: EPS is not tagged before 2017. 10 checks were skipped: revenue is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2016

Share this section

Download image